1. Home
  2. ICMB vs NCEL Comparison

ICMB vs NCEL Comparison

Compare ICMB & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Investcorp Credit Management BDC Inc.

ICMB

Investcorp Credit Management BDC Inc.

HOLD

Current Price

$0.87

Market Cap

17.2M

Sector

Finance

ML Signal

HOLD

Logo NewcelX Ltd. Ordinary Shares

NCEL

NewcelX Ltd. Ordinary Shares

HOLD

Current Price

$3.28

Market Cap

19.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICMB
NCEL
Founded
2012
2008
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2M
19.4M
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
ICMB
NCEL
Price
$0.87
$3.28
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
29.8K
6.9K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
21.74%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.43
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$1.83
52 Week High
$3.12
$5.12

Technical Indicators

Market Signals
Indicator
ICMB
NCEL
Relative Strength Index (RSI) 53.80 46.16
Support Level $0.86 $3.09
Resistance Level $0.89 $3.51
Average True Range (ATR) 0.03 0.17
MACD 0.01 0.01
Stochastic Oscillator 65.79 29.31

Price Performance

Historical Comparison
ICMB
NCEL

About ICMB Investcorp Credit Management BDC Inc.

Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: